Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract highlighting preclinical data from SG293, ...
Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this ...
If you bought XBI a year ago and held it, you are up roughly 65%. If you bought Direxion Daily S&P Biotech Bull 3X Shares ...
Legend Biotech Corporation looks like a J&J acquisition target as Carvykti sales surge and Phase 2 data impress. Click for ...
MarketBeat on MSN
3 biotech stocks that could benefit from the patent cliff
Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals ...
Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and ...
Lunai Bioworks uses a proprietary AI platform and biological validation to reverse-engineer diseases, aiming to reduce the 90 ...
We'll know more about the company's medium-term prospects by the end of the year.
LUND, SE / ACCESS Newswire / April 27, 2026 / Cantargia AB (Nasdaq Stockholm:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today announced ear ...
BioAge Labs said its investigational pill for cardiovascular risk prevention significantly reduced inflammation in an early ...
Crucially, Royalty Pharma’s model removes a lot of the volatility arising from development risk. By focusing on approved or ...
A new therapy has the potential to cure hundreds of diseases — and even reverse aging. Credit...Photo illustration by Kensuke ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results